IEZZI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 955
EU - Europa 582
AS - Asia 256
SA - Sud America 4
Totale 1.797
Nazione #
US - Stati Uniti d'America 955
CN - Cina 132
IE - Irlanda 127
SE - Svezia 103
IT - Italia 99
UA - Ucraina 72
FR - Francia 69
TR - Turchia 65
DE - Germania 37
GB - Regno Unito 32
IN - India 20
VN - Vietnam 20
SG - Singapore 15
RU - Federazione Russa 13
CZ - Repubblica Ceca 10
AT - Austria 7
FI - Finlandia 4
BE - Belgio 3
HK - Hong Kong 2
PY - Paraguay 2
RO - Romania 2
BR - Brasile 1
CL - Cile 1
DK - Danimarca 1
JP - Giappone 1
LT - Lituania 1
NL - Olanda 1
PL - Polonia 1
UZ - Uzbekistan 1
Totale 1.797
Città #
Chandler 237
Jacksonville 127
Dublin 126
Dearborn 90
Ashburn 56
Houston 55
Princeton 52
Izmir 39
Nanjing 39
Wilmington 28
Altamura 26
Chieti 26
Beijing 22
Ann Arbor 21
Boardman 20
Dong Ket 20
Southend 16
Cambridge 13
Kunming 12
Los Angeles 10
Nanchang 10
Singapore 10
Washington 10
Brno 9
New York 9
Shenyang 8
Jiaxing 7
Norwalk 7
Vienna 7
Tianjin 6
Hebei 5
Pescara 5
Hefei 4
London 4
Woodbridge 4
Brussels 3
Chicago 3
Falls Church 3
Hangzhou 3
Pune 3
Savigliano 3
Tappahannock 3
Asunción 2
Cerveteri 2
Changsha 2
Hong Kong 2
Leicester 2
Loreto Aprutino 2
Moscow 2
Palagiano 2
Rome 2
Santa Clara 2
Zhengzhou 2
Ameno 1
Amsterdam 1
Apo 1
Brdo 1
Campobasso 1
Castano Primo 1
Changchun 1
Colleferro 1
Copenhagen 1
Dallas 1
Edinburgh 1
Frankfurt am Main 1
Grevenbroich 1
Guangzhou 1
Gunzenhausen 1
Harbin 1
Hunedoara 1
Jinan 1
Jinhua 1
Lanciano 1
Medford 1
Milan 1
Nanning 1
Ningbo 1
Pieve 1
Redwood City 1
Seattle 1
Shaoxing 1
Spoltore 1
Stanford 1
Stockholm 1
São Paulo 1
Taizhou 1
Tashkent 1
Tokyo 1
Vilnius 1
Wenzhou 1
Totale 1.220
Nome #
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 103
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 93
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 89
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 86
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 85
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 82
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 79
null 79
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 79
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 78
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 77
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 76
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 75
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 74
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 73
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 73
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 73
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 72
Triple positive early breast cancer in the pre- and post Trastuzumab eras: a subgroup analysis of a multicenter retrospective study. 68
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 68
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 68
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 66
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 63
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 60
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 58
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting 50
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 25
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting 13
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 1
Totale 1.986
Categoria #
all - tutte 6.522
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.522


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020560 128 20 21 30 65 57 63 29 53 52 37 5
2020/2021139 20 1 31 2 7 30 3 4 5 5 3 28
2021/2022142 0 6 0 33 6 4 6 8 9 4 15 51
2022/2023561 38 75 38 77 48 100 22 55 69 7 21 11
2023/2024269 31 13 17 11 19 99 38 5 6 11 3 16
2024/202529 29 0 0 0 0 0 0 0 0 0 0 0
Totale 1.986